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Abstract
Treosulfan-based conditioning prior to allogeneic transplantation has been shown to have myeloablative, immunosuppres-
sive, and antineoplastic effects associated with reduced non-relapse mortality (NRM) in adults. Therefore, we prospectively
evaluated the safety and efficacy of treosulfan-based conditioning in children with hematological malignancies in this phase
II trial. Overall, 65 children with acute lymphoblastic leukemia (35.4%), acute myeloid leukemia (44.6%), myelodysplastic
syndrome (15.4%), or juvenile myelomonocytic leukemia (4.6%) received treosulfan intravenously at a dose of 10 mg/m2/
day (7.7%), 12 g/m2/day (35.4%), or 14 g/m2/day (56.9%) according to their individual body surface area in combination
with fludarabine and thiotepa. The incidence of complete donor chimerism at day +28 was 98.4% with no primary and only
one secondary graft failure. At 36 months, NRM was only 3.1%, while relapse incidence was 21.7%, and overall survival
was 83.0%. The cumulative incidence of acute graft-vs.-host disease was 45.3% for grades I–IV and 26.6% for grades II–IV.
At 36 months, 25.8% overall and 19.4% moderate/severe chronic graft-vs.-host disease were reported. These data confirm
the safe and effective use of treosulfan-based conditioning in pediatric patients with hematological malignancies. Therefore,
treosulfan/fludarabine/thiotepa can be recommended for myeloablative conditioning in children with hematological
malignancies.
Introduction
Children with hematological malignancies routinely
undergo either busulfan- or fractionated TBI-based mye-
loablative conditioning regimens prior to allogenic hema-
topoietic stem cell transplantation (alloHSCT). However,
both regimens are associated with a considerable risk of
acute and late serious adverse events (AEs) [1–5]. Clinical
studies, including prospective phase III trials in adults with
AML and MDS, have shown that treosulfan-based con-
ditioning has myeloablative, immunosuppressive, and
antineoplastic effects associated with a low non-relapse
mortality (NRM) [6–11]. Furthermore, several reports have
been published that show an indication for treosulfan-based
conditioning in children undergoing alloHSCT for non-
malignant and malignant disorders [12–21]. In addition,
pharmacokinetic (PK) investigations on treosulfan in chil-
dren have been conducted in order to derive dose recom-
mendations for all pediatric age groups [22–25]. We
therefore, prospectively evaluated treosulfan/fludarabine
conditioning in pediatric patients with hematological
malignancies during this extended clinical phase II trial.
Herein, we strictly applied an individual body surface area
(BSA)-adapted treosulfan dosing [26] with the option of
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Between November 2014 and July 2015, 70 children (aged
28 days to 17 years) with acute lymphoblastic leukemia
(ALL), acute myeloid leukemia (AML), myelodysplastic
syndrome (MDS), or juvenile myelomonocytic leukemia
(JMML) were enrolled in this prospective non-randomized
phase II trial at 18 transplantation sites in five European
countries. Written informed consent on all aspects of the
study was obtained from all children and/or their legal
guardians before enrollment. The study was approved by
the responsible independent ethics committees and compe-
tent authorities and was performed in accordance with the
Declaration of Helsinki, as well as Good Clinical Practice
guideline. Safety and outcome parameters of all surviving
patients were analyzed after a 36 months follow-up period
focusing on the 65 patients who were additionally treated
with thiotepa. The 5 out of 70 patients, who received
treosulfan and fludarabine only, were excluded from the
statistical analysis reported here. However, the key findings
for all 70 trial patients (including the five patients condi-
tioned only with treosulfan/fludarabine) are provided in
Fig. S1 in the online supplementary.
Donors and grafts
Either human leucocyte antigens (HLA)-identical siblings
(MSD), matched family donors, or matched unrelated
donors were eligible donors (Table 1). An HLA match was
defined as at least a 9/10 allele-matched after high-
Table 1 Summary of
demographic data and transplant
characteristics by disease.
Disease
ALL (N= 23) AML (N= 29) MDS (N= 10) JMML (N= 3) Overall (N= 65)
Sex [n (%)]
Male 15 (65.2%) 19 (65.5%) 5 (50.0%) 3 (100.0%) 42 (64.6%)
Female 8 (34.8%) 10 (34.5%) 5 (50.0%) 0 (0.0%) 23 (35.4%)
Age [years]
Mean (SD) 10.5 (5.6) 8.2 (5.6) 11.6 (5.7) 2.0 (2.0) 9.3 (5.8)
Median 12.0 8.0 14.0 2.0 11.0
Min., Max. 1, 17 0, 17 1, 17 0, 4 0, 17
ICH age group [n (%)]
28 days to 23 months 2 (8.7%) 4 (13.8%) 1 (10.0%) 1 (33.3%) 8 (12.3%)
2–11 years 7 (30.4%) 14 (48.3%) 2 (20.0%) 2 (66.7%) 25 (38.5%)
12–17 years 14 (60.9%) 11 (37.9%) 7 (70.0%) 0 (0.0%) 32 (49.2%)
Number of HSCT [n (%)]
1st 22 (95.7%) 28 (96.6) 8 (80) 2 (66.7%) 60 (92.3%)
2nd 1 (4.3%) 1 (3.4) 2 (20) 1 (33.3%) 5 (7.7%)
Number of complete remission [n (%)]a
1. CR 16 (69.6%) 25 (86.2%) na na 41 (63.1%)
2. CR 7 (30.4%) 3 (10.3%) na na 10 (15.4%)
3. CR (or higher) 0 (0.0) 1 (3.4%) na na 1 (1.5%)
Secondary origin of malignancy [n (%)]
Yes 1 (4.3) 0 (0.0) 4 (40) 0 (0.0) 5 (7.7)
Treosulfan dose [n (%)]
10 g/m2/day −6, −5, −4 1 (4.3%) 3 (10.3%) 0 (0.0%) 1 (33.3%) 5 (7.7%)
12 g/m2/day −6, −5, −4 5 (21.7%) 13 (44.8%) 3 (30.0%) 2 (66.7%) 23 (35.4%)
14 g/m2/day −6, −5, −4 17 (73.9%) 13 (44.8%) 7 (70.0%) 0 (0.0%) 37 (56.9%)
Donor type [n (%)]
Matched sibling 6 (26.1%) 4 (13.8%) 1 (10.0%) 0 (0.0%) 11 (16.9%)
Matched family 0 (0.0%) 1 (3.4%) 0 (0.0%) 0 (0.0%) 1 (1.5%)
Matched unrelated 17 (73.9%) 24 (82.8%) 9 (90.0%) 3 (100.0%) 53 (81.5%)
Source [n (%)]
Bone marrow 14 (60.9%) 13 (44.8%) 3 (30.0%) 3 (100.0%) 33 (50.8%)
Peripheral blood 9 (39.1%) 16 (55.2%) 7 (70.0%) 0 (0.0%) 32 (49.2%)
ALL acute lymphoblastic leukaemia, AML acute myeloid leukaemia, MDS myelodysplastic syndrome,
JMML juvenile myelomonocytic leukaemias, ICH International Council of Harmonization, Max. maximum,
Min. minimum, N number of subjects, n number of subjects in category, SD standard deviation, na not
applicable.
aFor ALL and AML subjects only.
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resolution four-digit typing in HLA-A*, B*, C* and DRB1*
and DQB1*.
Conditioning regimen and supportive care
All patients received an individualized BSA-adapted intra-
venous (IV) treosulfan dose on days −6 to −4, i.e., BSA
of ≤0.5 m2 received 10 g/m2/day; of >0.5–1.0 m2 received
12 g/m2/day; and of >1.0 m2 received 14 g/m2/day. Subse-
quently, fludarabine 30 mg/m2/day IV was given from day
−7 to day −3 (total dose: 150 mg/m2). At the investigator’s
discretion, thiotepa 2 × 5 mg/kg/day IV was additionally
given on day −2 to 65 patients (total dose: 10 mg/kg).
Allogeneic hematopoietic stem cells obtained either
from peripheral blood or from bone marrow were given
at day 0. Supportive care, including GvHD prophylaxis
and treatment, was performed according to center-specific
guidelines.
Endpoints and definitions
The objective of this phase II trial was to describe the safety
and efficacy of treosulfan administered as part of a stan-
dardized fludarabine-containing conditioning treatment and
to contribute to a PK model. Clinical endpoints included
engraftment and complete donor-type chimerism (defined as
≥95% donor cells), NRM, disease relapse/progression (RI),
relapse/progression-free survival (RFS/PFS), acute/chronic
GvHD, GvHD-free and relapse/progression-free survival
(GRFS) [27], cGvHD-free and relapse/progression-free
survival (CRFS) [27], and overall survival (OS).
NRM is defined as the probability of dying without pre-
vious occurrence of a relapse/progression of the underlying
disease. Relapse/progression and graft failures are con-
sidered competing events. For estimation of GRFS, events
were defined as acute GvHD of at least grade III, moderate
or severe chronic GvHD, and relapse/progression or death
(whichever occurred first). For CGRFS, events were defined
as moderate or severe chronic GvHD, relapse/progression or
death (whichever occurred first). All AEs except hepatic
sinusoidal obstruction syndrome (HSOS) and hepatic toxi-
cities were based on the Common Terminology Criteria for
Adverse Events (CTCAE, version 4.03) and evaluated until
100 days after alloHSCT. HSOS was evaluated accor-
ding to Jones et al. [28] and hepatic toxicities according to
Bearman [29]. Furthermore, treosulfan concentrations in
plasma from each patient were analyzed to calculate PK
parameters in a subset of patients. Blood samples were taken
immediately after treosulfan infusion and thereafter within
15–30 min, 1–2 h, 3–6 h, and 7–8 h. Further details of
bioanalytical methods and the model-based parameter cal-
culation have been previously described [26, 30].
Statistical considerations
Descriptive analyses were performed using frequency,
mean, standard deviation, median, and range, as appro-
priate. All time to event endpoints were measured from the
day of HSCT (except for cGvHD, which started 100 days
after HSCT) to the time of event or competing event, if
applicable. Patients alive without event (or competing
event) were censored at the last follow-up or at day +100
after HSCT for aGvHD. Kaplan–Meier estimates were used
for calculating OS, GRFS, and CRFS. Cumulative inci-
dences were used for estimating NRM, RI, aGvHD, and
conditional cumulative incidences for neutrophil/leukocyte/
platelet engraftment. Competing events were as follows:
relapse/progression and graft failure for NRM; deaths
without relapse/progression and graft failure for RI; death,
relapse/progression, and graft failure within 100 days after
the end of HSCT for aGvHD; death, disease relapse/pro-
gression, or the use of rescue therapies for engraftment.
Any changes in single laboratory values were docu-
mented separately instead of being included in the AE
analysis. Non-compartmental methodology was applied for
the PK analysis of treosulfan. Based on the individual
plasma concentration–time data, the following parameters
were determined using the actual sampling times for treo-
sulfan: Cmax, tmax, AUClast, AUC∞, t1/2term, CL, and Vd.
Mean and standard deviations were calculated for all PK
parameters, except for tmax, for which the median and range
were computed.
This trial was descriptive in nature, thus, p values (two
sided) were explorative, based on a significance level of 0.1.
The data were analyzed using Pearson chi-square test for
chimerism, the log-rank test for OS, GRFS, and CRFS, and
the Gray test for NRM, RI, a/cGvHD.
All analyses were predefined in the statistical analysis
plan. SAS software (version 9.4; SAS, Cary, NC, USA) was
used for statistical analyses.
Results
Demographics
Sixty-five pediatric Caucasian patients (aged 28 days to 17
years, median 11 years) with ALL [35.4%], AML [44.6%],
MDS [15.4%], or JMML [4.6%] were conditioned with
treosulfan, fludarabine, and thiotepa. Nearly all of the ALL
and AML patients were in first or second complete remission
and had received their first alloHSCT procedure. Patients
with MDS were classified as having refractory anemia with
excess blasts (50%) or refractory cytopenia (40%). Children
received alloHSCT between November 2014 and July 2015.
1998 K. Kalwak et al.
The median follow-up was 41.8 months (range for surviving
patients: 24.2–57.5 months).
Depending on their individual BSA, patients received
treosulfan IV at a dose of 10 g/m2/day (7.7%), 12 g/m2/day
(35.4%), or 14 g/m2/day (56.9%). Treosulfan was combined
with fludarabine and thiotepa in 65 of 70 patients at the
investigators’ discretion (Table 1).
Outcomes
Engraftment, graft failure, and chimerism
The number of patients achieving reconstitution of granu-
lopoiesis was 64 (98.5%). One patient (1.4%) died before
engraftment 15 days after alloHSCT. The maximum con-
ditional cumulative incidence of engraftment reached was
100% (90% CI: 97.7, 100.0) 43 days after HSCT. No
patient experienced primary graft failure, and one patient
(1.4%) with ALL had decreased neutrophils and leukocytes
counts, but presented 100% donor chimerism, for which the
patient received a stem cell boost 113 days post transplant.
The incidence of complete donor-type chimerism at visit
day +28 was 98.4% (90% CI: 92.8, 99.90), at visit day
+100 the incidence was 92.2% (90% CI: 84.3, 96.9), and at
12 months the incidence was 92.6% (90% CI: 83.8, 97.4)
(Table 2). In exploratory subgroup analyses, a statistically
significant influence on complete chimerism of underlying
disease (JMML with 0% at day +100), as well as 2nd
alloHSCT procedure was recorded (day +100: p < 0.001
influence of underlying disease, p= 0.0566 2nd HSCT). In
contrast, the treosulfan dose, donor type, or patients age
group did not significantly influence the incidence of
complete donor-type chimerism.
Non-relapse mortality and relapse/progression incidence
Overall, the cumulative incidence of NRM at 36 months
was 3.1% (90% CI: 0.0, 6.6). One patient with AML died
due to laryngeal hemorrhage 0.5 months after HSCT. A
second patient with MDS died due to multi organ failure
12.3 months after HSCT. Due to the low number of events,
no statistically significant difference in NRM was detected
among the three different treosulfan dose groups (Fig. 1a) or
within any other of the analyzed subgroups.
The cumulative incidence of relapse/progression (RI) at
36 months was 21.7% (90% CI: 13.2, 30.1). In the subgroup
analyses, no statistically significant impact was recorded for
treosulfan dose, donor type, or patient’s age group (Fig. 1b),
but was found for underlying disease (p < 0.0001). Relapse
incidences of ALL were 26.1%, AML 17.2%, MDS 0.0%,
and JMML 100%. In the case of a 2nd HSCT procedure, the
incidence of relapse/progression increased from 18.5 to
60.0% (p= 0.0140) considering that only five patients were
treated in a second procedure.
Relapse/progression-free survival
The 36-month Kaplan–Meier estimate of RFS/PFS was
73.6% (90% CI: 63.3, 81.5). In the exploratory subgroup
analyses a statistically significant impact was recorded for
2nd HSCT (1st HSCT [76.4%]; 2nd HSCT [40%]; p=
0.0234) and underlying disease (ALL [69.6%], AML
[79.3%], MDS [88.9%], JMML [0%]; p= 0.0001). How-
ever, in total only three JMML patients were included in the
trial. There was no difference in RFS/PFS among donor
types, age groups, and the three different treosulfan dose
groups (Figs. 1c and 2).
Graft-vs.-host disease
At 100 days, the cumulative incidence of acute GvHD was:
45.3% (90% CI: 35.1, 55.5) grades I–IV, 26.6% (90% CI:
17.5, 35.6) grades II–IV, and 7.8% (90% CI: 2.3, 13.3)
grades III–IV (Table 3). There was no difference among the
three different treosulfan dose groups (Fig. S2 in online
supplementary).
The cumulative incidence of chronic GvHD at 36 months
was 25.8% (90% CI: 16.7, 34.9) and that of moderate/
severe chronic GvHD was 19.4% (90% CI: 11.1, 27.7)
(Table 3 and Fig. S3 in the online supplementary). The ten
Table 2 Incidence of complete donor-type chimerism.
Treosulfan
Subjects at risk at day +28 visita N= 64
Subjects with complete chimerism at day +28 visit
[n (%)]
63 (98.4)
90% CI (92.8, 99.9)
Subjects without information at day +28 visit
[n (%)]
1 (1.6)
Subjects at risk at day +100 visita N= 64
Subjects with complete chimerism at day +100 visit
[n (%)]
59 (92.2)
90% CI (84.3, 96.9)
Subjects without information at day +100 visit
[n (%)]
5 (7.8)
Subjects at risk at month 12 visita N= 54
Subjects with complete chimerism at month 12 visit
[n (%)]
50 (92.6)
90% CI (83.8, 97.4)
Subjects without information at month 12 visit
[n (%)]
2 (3.7)
CI confidence interval, N number of subjects, n number of subjects in
category.
aSubjects are at risk if they have a chimerism examination at the day
+28, day +100, or month 12 visit or if they have survived day +30,
day +107, or day +379.
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MDS patients experienced a higher overall and moderate/
severe chronic GvHD incidences (60.0% [95% CI: 34.5,
85.5] and 52% [90% CI: 25.0, 79.9], respectively).
GvHD-free and relapse/progression-free survival (GRFS) and
cGvHD-free and relapse/progression-free survival (CRFS)
The 36-month Kaplan–Meier estimate of GRFS was 56.7%
(90% CI: 45.9, 66.1) (Fig. 3a). In the disease subgroups,
GRFS was 56.5% at 36 months for ALL, 69.0% for AML,
and 36.0% for MDS (JMML was not applicable). The five
patients who underwent a second HSCT experienced a
significantly lower incidence of GRFS with only 20.0%
(90% CI: 1.8, 52.2; p= 0.0105) compared with patients
after their first HSCT (59.7%; 90% CI: 48.5, 69.3).
The Kaplan–Meier estimate of CRFS at 36 months was
58.2% (90% CI: 47.4, 67.5) (Fig. 3b). In the disease sub-
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10 g/m2/day 5 5 4 4 4 4 4 0 0 0 0 0
12 g/m2/day 23 23 20 19 18 17 17 12 11 1 1 0
14 g/m2/day 37 35 31 29 28 26 25 13 11 1 0 0
5 5 4 4 4 4 4 2 0 0 0 0
23 23 22 19 18 17 17 14 11 6 1 0
37 35 33 32 28 26 25 19 12 8 0 0
10 g/m2/day 5 5 4 4 4 4 4 0 0 0 0 0
12 g/m2/day 23 23 20 19 18 17 17 12 11 1 1 0
14 g/m2/day 37 35 31 29 27 25 24 12 11 1 0 0
5 5 5 5 5 5 5 3 1 1 0 0
23 23 23 22 21 21 21 17 12 6 1 0
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10 g/m2/day 12 g/m2/day 14 g/m2/day
10 g/m2/day 12 g/m2/day 14 g/m2/day
10 g/m2/day 12 g/m2/day 14 g/m2/day
Number of subjects 5 23 37
Median [months] NA NA NA
(Min, Max)a (NA, NA) (NA, NA) (0.5, 12.3)
Rate at 36 months [%] 0.0 0.0 5.4
90% CI (0.0, 0.0) (0.0, 0.0) (0.0, 11.5)
Number of subjects 5 23 37
Events 1 (20.0%) 6 (26.1%) 10 (27.0%)
Censored 4 (80.0%) 17 (73.9%) 27 (73.0%)
Rate at 36 monthsb [%] 80.0 73.9 72.5
90% CI (31.4, 95.8) (55.3, 85.7) (58.2, 82.7)
Number of subjects 5 23 37
Median [months] NA NA NA
(Min, Max)a (3.6, 3.6) (3.7, 23.2) (2.2, 22.0)
Rate at 36 months [%] 20.0 26.1 19.2
90% CI (0.0, 49.4) (11.0, 41.1) (8.5, 29.9)
Number of subjects 5 23 37
Events 0 (0.0%) 2 (8.7%) 9 (24.3%)
Censored 5 (100.0%) 21 (91.3%) 28 (75.7%)
Rate at 36 monthsb [%] 100.0 91.3 75.6
90% CI (100.0, 100.0) (74.7, 97.2) (61.5, 85.1)
aMinimum and maximum of observed event times 
bBased on Kaplan-Meier estimates
a b
c d
Fig. 1 Treosulfan dose-dependent cumulative incidence of non-relapse mortality (a), relapse/progression (b), Kaplan–Meier estimate of relapse/
progression-free survival (c) and of overall survival (d).
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for MDS, and 0.0% for JMML patients (p= 0.0017).
Again, CRFS was worse after the second HSCT procedure
(20.0 vs. 61.4%; p= 0.0060), while treosulfan dose, donor
type, and age group did not influence this combined
endpoint.
Overall survival (OS)
At the time of the final analysis, 11 patients (16.9%) had
died. The causes of these deaths were relapse/progression
related in eight (12.3%) patients, and transplantation related
in three patients (4.6%).
The median time from transplantation to death was
9.72 months (Q1, Q3: 6.18, 17.25) with a range from 0.5 to
25.8 months. The 36-month Kaplan–Meier estimate of OS
after HSCT was 83.0% (90% CI: 73.7, 89.3) (Fig. 4). OS
estimates in ALL (78.3%), AML (86.2%), and MDS (90%)
were comparable, while of the three JMML patients two
survived. OS estimates in the ICH age groups were com-
parable to the treosulfan dose groups. Exploratory analysis
indicated that there was a higher OS in eight patients aged
28 days to 23 months (100%, 90% CI: 100, 100) than in the
32 patients aged 12–17 years (74.9%, 90% CI: 59.5, 85.1).
Accordingly (due to the individual BSA-related dose cal-
culation), OS was 100% in the 10 g/m² treosulfan group and
75.6% (90% CI: 61.5, 85.1) in the 14 g/m² dose group
(Fig. 1d). The five patients who received a 2nd HSCT had a
lower OS probability at 36 months (60%, 90% CI: 19.1,
85.4) in comparison with the 60 patients who received a 1st
alloHSCT procedure (85%, 90% CI: 75.4, 91.0).
Adverse events and pharmacokinetic results
Treatment-emergent AEs were reported in 63 of 65 patients
(96.9%). The most common CTCAE terms with severity of
at least grade III were mucositis—oral (43.1%), infections
and infestations—other (30.8%), nausea and vomiting (both
16.9%), and diarrhea (15.4%) (Table 4). Skin and sub-
cutaneous tissue disorders of at least CTCAE grade III were
reported in 12.3% of the patients. One patient (1.4%)
developed HSOS (grade II according to Jones et al. [28])
and recovered after 22 days.
A total of 290 PK samples from 54 patients were ana-
lyzed. The mean AUClast (±SD) was comparable among the
three different dose groups (1686 ± 345 μg h/mL [10 g/m2],
1599 ± 33 μg h/mL [12 g/m2], and 1848 ± 283 μg h/mL
[14 g/m2]) as evaluated in the PK subset of trial patients. In
addition, the median Cmax was comparable among the dif-
ferent dose or BSA groups (700 ± 218 μg/mL [10 g/m2],
634 ± 192 μg/mL [12 g/m2], and 650 ± 98 μg/mL [14 g/m2])
reflecting the individualized dose calculation based on
BSA (Table 5). However, treosulfan plasma clearance and
volume of distribution increased in the different dose
groups. This observation is most likely based on the
N n Rate at 36 months [%] (90% CI)
Overall 65 17 73.6  (63.3, 81.5)
Disease
ALL 23 7 69.6  (50.8, 82.3)
AML 29 6 79.3  (63.5,88.8)
MDS 10 1 88.9  (54.3, 97.8)





5 1 80.0  (31.4, 95.8)
23 6 73.9  (55.3, 85.7)
37 10 72.5  (58.2, 82.7)
Number of HSCT
1st 60 14 76.4  (65.9, 84.1)
2nd 5 3 40.0  (8.6, 71.0)
Donor type
MRD 12 1 91.7  (63.7, 98.3)
MUD 53 16 69.5  (57.7, 78.6)
CTP age group
28 days to < 10 years 32 9 71.9  (56.4, 82.7)
10 years to < 18 years 33 8 75.3  (60.2, 85.4)
ICH age group
28 days to 24 months 8 1 87.5  (50.0, 97.5)
2 to 11 years 25 8 68.0  (50.0, 80.7)
12 to 17 years 32 8 74.5  (59.0, 84.9)
N = number of subjects; n = number of events. *Rate at 36 months
not available, therefore rate at end of documentation displayed. 
 
Rate at 36 months [%]
6040200 80 100
Fig. 2 Forest plot for relapse/
progression-free survival
displaying 36 months rates by
subgroups.
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different ages, and BSA of the patients represented within
the different dose groups.
Discussion
After initial data on treosulfan-based conditioning in adult
alloHSCT patients became available [9, 10], several pub-
lished studies reported on the efficacy and safety of treo-
sulfan given as part of various conditioning regimens in
children [12, 13, 15, 16, 20, 31]. Here, we report the final
results of the first prospective alloHSCT trial of a treo-
sulfan/fludarabine/thiotepa combination regimen (FTT; 65
of 70 trial patients treated) administered to children and
adolescents with hematological malignancies. In this study,
an individual BSA-adapted dose calculation was con-
sistently applied for treosulfan.
The 36-month Kaplan–Meier estimates of 3.1% for NRM,
83.0% for OS, and 73.6% for RFS/PFS compare favorably
with the survival data reported for other conditioning
regimens [2–5]. Overall, the 36-month relapse rate was
low (21.7%), although three patients with JMML relapsed
between 6 and 9 months post transplant. Disease recurrence is
known to be particularly high in patients with JMML given an
allograft, but the percentage of relapse seems to be higher
than that reported using the busulfan/cyclophosphamide/
melphalan regimen [32]. However, due to the very low
number of JMML patients, no conclusions can be drawn at
this point in time. On the other hand, the 36-month relapse
incidence of 26.1% for the ALL subgroup (23 patients) is
probably comparable to that of standard TBI-based regimens.
Table 3 Summary of cumulative incidence of acute and
chronic GvHD.
aGvHD Treosulfan (N= 65)
Grades I–IV
Subjects with event [n (%)] 29 (44.6%)
Cumulative incidence of acute GvHD at
100 days (%)
45.3
90% CI (35.1, 55.5)
Grades II–IV
Subjects with event [n (%)] 17 (26.2%)
Cumulative incidence of acute GvHD at
100 days (%)
26.6
90% CI (17.5, 35.6)
Grades III–IV
Subjects with event [n (%)] 5 (7.7%)
Cumulative incidence of acute GvHD at
100 days (%)
7.8
90% CI (2.3, 13.3)
Overall
Subjects with event [n (%)] 16 (25.8%)
Cumulative incidence of cGvHD at
36 months (%)
25.8
90% CI (16.7, 34.9)
Moderate/severe
Subjects with event [n (%)] 12 (19.4%)
Cumulative incidence of cGvHD at
36 months (%)
19.4
90% CI (11.1, 27.7)
CI confidence interval, aGvHD acute graft-vs.-host disease, cGvHD
chronic graft-vs.-host disease, N number of subjects, n number of
subjects in category.
Time [months]




































Treosulfan 65 58 48 41 40 35 34 18 17 2 1 0
Subjects at risk
Number of subjects at risk 65
Events 28 (43.1%)
Censored 37 (56.9%)
Rate at 36 monthsa [%] 56.7
90% CI (45.9, 66.1)
GvHD-free and relapse/progression-free survival
Time [months]


































Treosulfan 65 63 49 42 41 36 35 19 18 2 1 0
Subjects at risk
Number of subjects at risk 65
Events 27 (41.5%)
Censored 38 (58.5%)
Rate at 36 monthsa [%] 58.2
90% CI (47.4, 67.5)
Chronic GvHD-free and relapse/progression-free survival
Note: ‘GvHD-free’ defined as no acute GvHD of at least grade III and no moderate/severe
chronic GvHD. ‘Chronic GvHD-free’ defined as no moderate/severe chronic GvHD.
aBased on Kaplan-Meier estimates
Fig. 3 Kaplan–Meier estimates of (a) GvHD-free and relapse/pro-
gression-free survival and (b) chronic GvHD-free and relapse/pro-
gression-free survival.
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Numerically, it might be slightly higher compared with the
data published by Peters et al. [2]. The value of TBI-based
and chemotherapy-based conditioning in childhood ALL is
currently being investigated in an international controlled
phase III trial (EudraCT No.: 2012–003032–22; Clin-
icalTrials.gov Identifier: NCT01949129). The relapse inci-
dence of 17.2% at 36 months for the 29 AML patients and
of 0% for the 10 MDS patients compares favorably with
that reported for busulfan-based conditioning treatments
[2, 33, 34]. Excellent results of the FTT regimen in children
with AML (low relapse rate and reduced toxicity) warrant
assessing this regimen in a prospective randomized pediatric
alloHSCT trial in Europe, comparing busulfan- and
treosulfan-based conditioning regimens for AML.
All patients achieved neutrophil engraftment and 98.4%
of patients had a complete donor chimerism by day +28
post transplant. While neutrophil engraftment was com-
parable to that of previous reports [12, 20, 31], no pro-
spective trial data on chimerism have been previously
reported in children with malignant disorders who received
conditioning with FTT. Hence, this study provides con-
firmation of the myeloablative potential of a FTT con-
ditioning regimen, which results in an excellent rate of
complete donor-type chimerism.
There were no primary graft failures. One ALL patient
developed secondary poor graft function with decreasing
blood cell counts associated with a viral illness despite
100% donor chimerism and received a stem cell boost.
The incidence of liver toxicity was relatively low with
only one case (1.5%) of grade II HSOS, which resolved
under appropriate therapy, compared with an up to 22%
HSOS incidence reported in busulfan-containing regimens
[3, 35]. Moreover, skin and subcutaneous tissue disorders of
at least CTCAE grade III were within an acceptable range
(12.3%) despite the intensification of the regimen with the
addition of thiotepa. Just over half of the patients developed
gastrointestinal (GI) AEs of at least CTCAE grade III, while
oral mucositis was most prominent (43.1%). Compared
with the data published by Boztug et al. [20], GI toxicity
was relatively frequent, but not life-threatening, and was
probably promoted by the addition of thiotepa in the vast
majority of patients.
Unlike previous reports [22–25], we observed a rather
limited variability in interindividual PKs of treosulfan. The
BSA-banded dose calculation applied in this trial achieved
equivalent treosulfan exposure (AUC, Cmax) in all dose
groups. In the dose subgroups, the differences in outcome
parameters, such as overall survival, were therefore, prob-
ably not due to a higher treosulfan exposure, but may be
related to specific patient-, graft-, and/or underlying disease
characteristics. The wide age range of patients included in
this trial (from 28 days to 17 years of age) is reflected by the
increase in treosulfan plasma clearance and volume of
Time [months]


















Treosulfan 65 64 63 59 56 55 53 41 25 15 1 0
Subjects at risk
Number of subjects at risk 65
Events 11 (16.9%)
Censored 54 (83.1%)
Rate at 36 monthsa [%] 83.0
90% CI (73.7, 89.3)
aBased on Kaplan-Meier estimates 
Fig. 4 Kaplan–Meier estimate of overall survival.
Table 4 Frequency of patients with treatment emergent adverse events
of at least CTCAE grade III in at least 10% of patients by System
Organ Class and Preferred Term (MedDRA 20.0).
CTCAE System Organ Class CTCAE Term Treosulfan (N= 65)
Subjects with any event 50 (76.9%)
Gastrointestinal disorders






Abdominal pain 1 (1.5%)
Esophageal pain 1 (1.5%)
Typhlitis 1 (1.5%)
Upper gastrointestinal hemorrhage 1 (1.5%)
Infections and infestations
Any event 28 (43.1%)
Infections and infestations—other, specify 20 (30.8%)
Catheter-related infection 6 (9.2%)
Sepsis 4 (6.2%)
Bladder infection 3 (4.6%)
Urinary tract infection 3 (4.6%)
Encephalitis infection 1 (1.5%)
Hepatitis viral 1 (1.5%)
Laryngitis 1 (1.5%)
Skin infection 1 (1.5%)
Soft tissue infection 1 (1.5%)
Upper respiratory infection 1 (1.5%)
Absolute and relative frequencies of subjects with event relative to the
total number of subjects (N).
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distribution within the different dose groups. Apparently,
this observation is not related to treosulfan dose, but rather
to the age-related differences in organ function maturation
that are taken into account in the BSA-dependent dose
calculation. Therefore, the strict application of the indivi-
dual BSA-dependent treosulfan dose calculation should
remain valid for the pediatric population [26].
There are several limitations to this prospective phase II
study. Only a small number of patients were treated, espe-
cially in the MDS and JMML subgroups. Consequently, the
poor outcome reported for JMML patients should be treated
with caution. However, at least one JMML patient was
considered at increased risk due to his second alloHSCT
procedure.
The NRM, incidence of early toxicities, and donor chi-
merism, though, are likely to remain stable beyond this
reported 36-month observation period. We can thus, safely
conclude that FTT conditioning achieves high rates of
engraftment with relatively low toxicity. Based on these and
other clinical data, the European Commission has most
recently approved treosulfan for conditioning in pediatric
patients older than 1 month with malignant diseases [36].
We conclude that treosulfan-based conditioning with
BSA-adapted dosing is safe and effective in pediatric
patients with hematological malignancies. The cumulative
incidences of OS and NRM compare favorably with those
reported for other conditioning regimens. Treosulfan/flu-
darabine/thiotepa is, therefore, recommended as a suitable
myeloablative preparative treatment for this pediatric
patient population.
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Table 5 Pharmacokinetic results
of treosulfan stratified by BSA-
dependent dose group (non-
compartmental analysis).
Mean ± SD, tmax: median (range) 10 g/m² 12 g/m² 14 g/m²
N 5 23a 26
Cmax [μg/mL] 700 ± 218 634 ± 192 650 ± 98
tmax [h] 2.28 (2.00–2.30) 2.00 (2.00–2.50) 2.02 (2.00–2.65)
AUClast [μg h/mL] 1686 ± 345 1599 ± 33 1848 ± 283
AUC∞ [μg h/mL] 1700 ± 351 1627 ± 344 1900 ± 296
t1/2term [h] 1.15 ± 0.12 1.38 ± 0.21 1.59 ± 0.18
CL [L/h] 2.33 ± 0.60 5.3 ± 1.35 10.94 ± 2.41
Vd [L] 3.86 ± 1.11 10.78 ± 3.69 25.24 ± 6.64
aN= 25 for AUC∞, t1/2term, CL, Vd.
SD standard deviation, tma time to reach maximum plasma concentration, N number of subjects, Cmax
maximum plasma concentration, h hour, AUC area under the curve, AUClas AUC from time 0 to the time of
the last measurable plasma concentration, AUC∞ AUC from time 0 to infinite time, t1/2term apparent terminal
elimination half-life, CL total clearance; Vd volume of distribution.
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